Search

Your search keyword '"Ye, Qin"' showing total 1,712 results
Start Over Author "Ye, Qin"
1,712 results on '"Ye, Qin"'

8. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains

Author

Li Chen, Mengmeng Sun, Huajun Zhang, Xinghai Zhang, Yanfeng Yao, Ming Li, Kangyin Li, Pengfei Fan, Haiwei Zhang, Ye Qin, Zhe Zhang, Entao Li, Zhen Chen, Wuxiang Guan, Shanshan Li, Changming Yu, Kaiming Zhang, Rui Gong, and Sandra Chiu

Subjects
Science
Abstract

Abstract Nipah virus (NiV) is a World Health Organization priority pathogen and there are currently no approved drugs for clinical immunotherapy. Through the use of a naïve human phage-displayed Fab library, two neutralizing antibodies (NiV41 and NiV42) targeting the NiV receptor binding protein (RBP) were identified. Following affinity maturation, antibodies derived from NiV41 display cross-reactivity against both NiV and Hendra virus (HeV), whereas the antibody based on NiV42 is only specific to NiV. Results of immunogenetic analysis reveal a correlation between the maturation of antibodies and their antiviral activity. In vivo testing of NiV41 and its mature form (41-6) show protective efficacy against a lethal NiV challenge in hamsters. Furthermore, a 2.88 Å Cryo-EM structure of the tetrameric RBP and antibody complex demonstrates that 41-6 blocks the receptor binding interface. These findings can be beneficial for the development of antiviral drugs and the design of vaccines with broad spectrum against henipaviruses.

Published
2024
Full Text
View/download PDF

12. Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer

Author

Yiyu Wang, Meng Sun, Zhong He, Ying Han, Yinhong Song, Jianjia Liang, Huimin Wang, Ye Qin, and Zhangshuang Deng

Subjects
Citrus, Polymethoxyflavones, Estrogen receptor, Ubiquitination, Tamoxifen, Science (General), Q1-390, Social sciences (General), H1-99
Abstract

Estrogen receptor-positive (ER+) breast cancer seriously endangers the women's physical and mental health worldwide and ER targeting therapy is vital. Here, we found that a citrus polymethoxyflavones (PMFs)-rich hydrolysate (C–H) and its major components (nobiletin and 3-methoxynobiletin) potently degrade ERα protein via the ubiquitin-proteasome pathway, thereby impairing the proliferation of ER+ breast cancer cells. Moreover, our study exhibited that C–H combined with tamoxifen (TAM) inhibited the cell proliferation of ER+ breast cancer in vitro. It was further confirmed that C–H decreased tumor growth of ER+ breast cancer in tumor-bearing 129 mice in vivo and improved the efficacy of tamoxifen. Our study revealed that the citrus PMFs have potential applications as pharmaceutical and healthcare products in breast cancer treatment by targeting ERα protein degradation.

Published
2024
Full Text
View/download PDF

34. Screening tumor stage-specific candidate neoantigens in thyroid adenocarcinoma using integrated exome and transcriptome sequencing

Author

Meng Jia, Jiawen Liang, Zhuyao Li, Ye Qin, Qianqian Li, Jianwei Wang, and Xiubo Lu

Subjects
thyroid carcinoma, neoantigens, machine learning, immune, prognosis, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundThe incidence of thyroid carcinoma (THCA), the most common endocrine tumor, is continuously increasing worldwide. Although the overall prognosis of THCA is good, patients with distant metastases exhibit a mortality rate of 5-20%.MethodsTo improve the diagnosis and overall prognosis of patients with thyroid cancer, we screened specific candidate neoantigen genes in early- and late-stage THCA by analyzing the transcriptome and somatic cell mutations in this study.ResultsThe top five early-stage neoantigen-related genes (NRGs) were G protein-coupled receptor 4 [GPR4], chondroitin sulfate proteoglycan 4 [CSPG4], teneurin transmembrane protein 1 [TENM1], protein S 1 [PROS1], and thymidine kinase 1 [TK1], whereas the top five late-stage NRGs were cadherin 6 [CDH6], semaphorin 6B [SEMA6B], dysferlin [DYSF], xenotropic and polytropic retrovirus receptor 1 [XPR1], and ABR activator of RhoGEF and GTPase [ABR]. Subsequently, we used machine learning models to verify their ability to screen NRGs and analyze the correlations among NRGs, immune cell types, and immune checkpoint regulators. The use of candidate antigen genes resulted in a better diagnostic model (the area under the curve [AUC] value of the early-stage group [0.979] was higher than that of the late-stage group [0.959]). Then, a prognostic model was constructed to predict NRG survival, and the 1-, 3- and 5-year AUC values were 0.83, 0.87, and 0.86, respectively, which were closely related to different immune cell types. Comparison of the expression trends and mutation frequencies of NRGs in multiple tumors revealed their potential for the development of broad spectrum therapeutic drugs.ConclusionIn conclusion, the candidate NRGs identified in this study could potentially be used as therapeutic targets and diagnostic biomarkers for the development of novel broad spectrum therapeutic agents.

Published
2023
Full Text
View/download PDF

40. Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

Author

Lei Bao, Ping Zhu, Yuan Mou, Yinhong Song, and Ye Qin

Subjects
LSD1, immunotherapy, PD-(L)1, tumor microenvironment, combination therapy, Immunologic diseases. Allergy, RC581-607
Abstract

Lysine-specific demethylase 1 (LSD1) is an enzyme that removes lysine methylation marks from nucleosome histone tails and plays an important role in cancer initiation, progression, metastasis, and recurrence. Recent research shows that LSD1 regulates tumor cells and immune cells through multiple upstream and downstream pathways, enabling tumor cells to adapt to the tumor microenvironment (TME). As a potential anti-tumor treatment strategy, immunotherapy has developed rapidly in the past few years. However, most patients have a low response rate to available immune checkpoint inhibitors (ICIs), including anti-PD-(L)1 therapy and CAR-T cell therapy, due to a broad array of immunosuppressive mechanisms. Notably, inhibition of LSD1 turns “cold tumors” into “hot tumors” and subsequently enhances tumor cell sensitivity to ICIs. This review focuses on recent advances in LSD1 and tumor immunity and discusses a potential therapeutic strategy for combining LSD1 inhibition with immunotherapy.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results